Home » Newsletters » BioWorld Science

BioWorld Science

June 1, 2000

View Archived Issues

Immune Network Research will license two Meditech compounds

Final results of ALLHAT published in JAMA

Combined therapy with estrogen and T-cell receptor protein for MS

Researchers report Atrigel containing leuprolide acetate may offer clinical advantages

Pharmacyclics updates status of products in clinical trials

Teijin/TAP gout treatment now also in clinical trials outside Japan

Combination of MDR modulator LY-335979 and docetaxel advances to phase II

Vivus seeks E.U. marketing approval for Alibra

Phthalocyanines and their use in cancer PDT patented by Brown

Ceramide derivatives synthesized at Otsuka may have potential in cognitive disorders, inflammation

Phase III results for Orthovisc disappointing

Acute effects of MCC-555 on gluconeogenesis in hepatocytes

Inhibitor of iNOS attenuates pancreatic beta-cell injury

Vasoactive diadenosine polyphosphates isolated and characterized by German investigators

Human Genome Sciences to begin phase II trials of repifermin in ulcerative colitis

In vivo effects of BMS-189921 on NEP and ACE reported at hypertension meeting

Dosmalfate launched in Spain for prophylaxis of gastric lesions and ulcers

Neisseria outer membrane proteins useful for the therapy, diagnosis of infections

Topical formulations of CMI-392, a dual PAF antagonist and 5-LO inhibitor

Janssen evaluating combination therapies for Alzheimer's disease and psychosis

Anticonvulsants reported useful for alcohol addiction and abuse

Suntory researchers discover novel neuroprotective agents

Antitumor indenoisoquinolines presented in patent literature

New carbapenem antibiotics with broad-spectrum activity prepared at Wyeth Lederle Japan

Antiplatelet effects reported for new cell adhesion inhibitors from Takeda

Orally bioavailable thrombin inhibitors designed at Pfizer

Flt-1 receptor-targeting ribozyme shows good tolerance, favorable pharmacokinetics in the clinic

Genelabs begins NDA submission of GL-701 for treatment of lupus

DMXAA demonstrates antivascular and cytokine-inducing effects in humans

CEP-701 associated mainly with mild to moderate GI toxicity in phase I trial in cancer patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...